Major hemorrhagic complications have been reported in about 5.5% of patients with myeloproliferative disorders, which are more common among patients with essential thrombocytosis. In contrast, the reported risk of bleeding in transbronchial biopsy is 1.9%(1). Major factors predisposing risk factors for postbiopsy bleeding include history of receiving anticoagulation, thrombocytopenia, or uremia. We present the case of fatal hemorrhage after transbronchial biopsy in a patient with essential thrombocytosis with a platelet count of 1,172 k/μl and with a background of myelofibrosis.